IART at a glance
INTEGRA LIFESCIENCES HOLDINGS CORP (IART, SEC CIK 917520) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 21, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $1.6 billion (up 1.5% from FY2024) and a net loss of $516.5 million. Diluted EPS was -$6.74.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding INTEGRA LIFESCIENCES HOLDINGS CORP (IART) shares worth $648.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.6B
- +1.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $648.4M · −1 vs prior quarter
- Latest 8-K
- Oct 21, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Carried-forward risks remain governed by the previously filed annual report
Management Discussion & Analysis
- Revenue $411.2M, up $9.1M YoY from $402.1M, low-single-digit growth
- Specialty Surgery $304.1M, up 4% YoY; Tissue Reconstruction $107.1M, down 2%
- Gross margin 51.0% vs 51.5% YoY; operating expenses 46.4% vs 48.5%
- Cash $252.3M vs $235.0M at December 31, 2025; nine-month operating cash flow $128.6M vs $38.6M
- Cincinnati disruption reduced revenue approximately $7M; facility recovery expected during second quarter 2027, SurgiMend relaunch targeted fourth quarter 2026
AI summary of the IART 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $411.2M, up 2.3%, despite approximately $7M Cincinnati flood disruption
- Adjusted EPS $0.59 versus $0.54, while adjusted gross margin fell to 61.1% from 62.9%
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1
- Press release includes organic revenue and adjusted EPS guidance, but GAAP guidance unavailable due to unpredictable expenses and foreign exchange
Item 7.01: Regulation FD Disclosure
- Closing of credit agreement and notes offering announced on October 19, 2026
- New financing provides capital but increases debt obligations and future interest requirements
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01 for details on a newly created direct financial obligation
- Investors must review Item 1.01 to assess obligation size, terms, maturity and potential balance-sheet impact
Item 1.01: Entry into a Material Definitive Agreement
- $1.65B secured credit package: $600M revolver, $600M Term Loan A, $450M Term Loan B
- $450M senior secured notes at 9.500%, maturing November 1, 2033
Item 1.02: Termination of a Material Definitive Agreement
- Existing Credit Agreement fully repaid and terminated on October 19, 2026
- Refinancing funded with Credit Agreement borrowings and Notes offering proceeds
Item EX-99.1: Item EX-99.1
- $450.0M senior secured notes issued at 9.500%, maturing 2033, increasing fixed-cost debt burden
- Refinanced approximately $1.65B credit facility, including $600M revolver, $600M term loan A and $450M term loan B
Item EX-99.1: Item EX-99.1
- $450M senior secured notes priced at 9.500%, maturing 2033
- High coupon signals elevated refinancing cost and increased interest burden
Item 7.01: Regulation FD Disclosure
- $450 million senior secured notes priced at 9.500%, maturing 2033
- Refinancing likely to raise Integra’s effective interest rate near the high end of management’s 100-200 basis-point range
AI summaries of IART 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IART
Don't miss the next IART filing
- Alerts as it files. A push when IART files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IART, by share count.
- Ask anything. An AI agent that reads every IART filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Veillon-Berteloot Chantal | F | Sep 1, 2026 | 1,455 | $16.62 |
| Knight Lea Daniels | F | Jul 3, 2026 | 5,226 | $18.05 |
| Singh Harvinder | A | Jul 1, 2026 | 5,590 | - |
| Mosebrook Jeffrey | F | Jul 1, 2026 | 937 | $17.89 |
| DAVIS ROBERT T. JR. | A | Jul 1, 2026 | 11,180 | - |
| McBreen Michael J. | A | Jun 1, 2026 | 60,372 | - |
| McBreen Michael J. | A | Jun 1, 2026 | 31,909 | - |
| BRADLEY KEITH | F | May 9, 2026 | 882 | $13.92 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.6B | $1.6B |
| Operating Income | - | $28.4M | -$493.4M |
| Net Income | $67.7M | -$6.9M | -$516.5M |
| Op. Margin | - | 1.8% | -30.2% |
| Net Margin | - | -0.4% | -31.6% |
| Balance Sheet | |||
| Total Assets | $3.8B | $4.0B | $3.6B |
| Equity | - | $1.5B | $1.0B |
| ROE | - | -0.4% | -49.5% |
| Per Share | |||
| EPS | $0.84 | $-0.09 | $-6.74 |
| Cash Flow | |||
| Operating CF | - | $129.4M | $50.4M |
| CapEx | $66.9M | $104.4M | $81.4M |
Source: XBRL data in INTEGRA LIFESCIENCES HOLDINGS CORP (IART)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IART share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $648.4M |
| Q2 2026 | 31 | $682.6M |
| Q1 2026 | 29 | $352.3M |
| Q4 2025 | 28 | $463.0M |
| Q3 2025 | 28 | $542.9M |
| Q2 2025 | 28 | $471.8M |
| Q1 2025 | 26 | $604.8M |
| Q4 2024 | 21 | $419.9M |
- Dimensional Fund Advisors+548.8K (+25%)
- Invesco Ltd+415.0K (+11%)
- JPMorgan Chase & Co+391.8K (+183%)
- Bank of America Corp+325.7K (+25%)
- Vanguard Portfolio Management LLC+196.7K (+5%)
- Millennium Management−1.01M (-70%)
- Wells Fargo & Co−45.2K (-71%)
- Allstate−41.2K (-67%)
- Two Sigma Investments−36.1K (-20%)
- Citigroup−27.6K (-63%)
- Citadel Advisors LLC+544.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IART filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Oct 23, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 8-K | Oct 19, 2026 | - | Analysis | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 3, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 5, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
IART SEC filings: frequently asked questions
Which institutions hold IART stock?
As of September 30, 2026, the largest INTEGRA LIFESCIENCES HOLDINGS CORP (IART) holders among the 13F filers tracked by SignalX were BlackRock ($176.2 million), Invesco Ltd ($67.8 million), Vanguard Portfolio Management LLC ($64.1 million), Morgan Stanley ($60.9 million), State Street Corp ($49.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IART's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $1.6 billion (up 1.5% from FY2024) and a net loss of $516.5 million. Diluted EPS was -$6.74. The figures come from the XBRL data in the 10-K.
What did IART report in its latest 8-K?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $411.2M, up 2.3%, despite approximately $7M Cincinnati flood disruption.
What are the latest IART SEC filings?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 23, 2026, an 8-K current report on October 21, 2026 and a Form 4 insider filing on September 4, 2026.
What is IART's SEC CIK number?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)'s SEC Central Index Key (CIK) is 917520. EDGAR lists every IART filing under that number.
Ask anything about IART
The research agent reads IART's filings, financials, insider trades and 13F holders, then answers with sources.